Today's Rundown Featured Story | | | Tuesday, October 29, 2019 Pfizer has dumped a bispecific antibody developed through its collaboration with MacroGenics. The solid tumor drug was the first partner-developed program based on MacroGenics' bispecific platform to enter the clinic but it has fallen before clearing phase 1. |
|
|---|
|
|  | White Paper: Rise in Targeted Therapies Biologics have experienced steady double-digit growth over the last 15 years. Precision medicine is also on the rise. Learn more about what to look for when navigating this new era of small-volume manufacturing. |
Top Stories Tuesday, October 29, 2019 Mirati Therapeutics’ KRAS G12C inhibitor MRTX849 has cleared its first clinical hurdle. The startup posted initial clinical data that suggest MRTX849 can hold its own against Amgen’s rival cancer drug, although the small numbers of patients treated to date make it impossible to draw firm conclusions. Tuesday, October 29, 2019 The public markets have been receptive to early-stage companies, but will the IPO remain open for these young companies? Or is it a bubble set to burst? We asked some of our 2019 Fierce 15 winners at this year’s awards reception what they thought and whether they would follow suit with a speedy IPO. Monday, October 28, 2019 Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts, authentic position within the chromosome. Tuesday, October 29, 2019 MorphoSys and Galapagos are cutting off development of their Novartis-backed drug MOR106 in atopic dermatitis. Tuesday, October 29, 2019 Not a bad day’s work for Atlas-seeded startup Disc Medicine: It’s managed a healthy $50 million series A, led by Novo Nordisk’s VC arm, gained a new executive chair from Nimbus and nabbed a deal with AbbVie. Tuesday, October 29, 2019 Researchers at the Francis Crick Institute have identified a key mechanism that controls how cancer cells degrade their surrounding scaffolds to migrate to other locations. Targeting the process could with drugs could stop cancer from spreading, they argue. Monday, October 28, 2019 After a few long years of watching from the sidelines as its rivals dove into immuno-oncology’s most coveted market, AstraZeneca finally has a study win in previously untreated non-small cell lung cancer. Monday, the British drugmaker said a combination of Imfinzi, CTLA4 candidate tremelimumab and chemo outperformed solo chemo at keeping patients’ cancer from progressing. |  | QUALITY. SPEED. VALUE.
You Can Have All Three We deliver potent, picomolar-affinity, development-ready human antibodies in a greater number and a shorter timeline than other CROs using transgenic animals, in vitro display or humanization, including for difficult targets such a GPCRs. Contact us at info@alivamab.com to learn more. alivamab.com |
Resources Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 
